| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13G · 1 security · passive | ||||||
|
Entrada Therapeutics, Inc.
13G/A
TRDA · 29384C108
|
6.9% |
2/14/2025
Event 12/31/2024
|
||||
| Roche Finance Ltd | 6.9% | |||||
| Roche Holding Ltd | 6.9% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.